Spectral AI (MDAI) Stock Overview
An artificial intelligence (AI) company, focuses on predictive medical diagnostics in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
MDAI Community Fair Values
Create NarrativeSee what 36 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Spectral AI, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.05 |
| 52 Week High | US$3.21 |
| 52 Week Low | US$1.13 |
| Beta | 0.91 |
| 1 Month Change | 39.46% |
| 3 Month Change | 17.14% |
| 1 Year Change | 58.91% |
| 3 Year Change | -80.19% |
| 5 Year Change | -78.97% |
| Change since IPO | -78.87% |
Recent News & Updates
MDAI: BARDA Funding And New Leadership Will Support Future Commercialization Potential
Analysts have updated their price targets on Spectral AI to reflect revised assumptions for discount rates, revenue growth, profit margins, and a higher forward P/E. These changes have resulted in a revised assessment of the potential upside in the shares.
MDAI: BARDA Funding And Leadership Transition Will Support Future Burn Preparedness
Analysts have nudged their Spectral AI price target to $6.00, citing small adjustments to assumptions on discount rate, revenue trends, profit margins, and a very high future P/E multiple as key drivers of the updated view. What's in the News Spectral AI received $31.7 million in immediate, non dilutive funding from the Biomedical Advanced Research and Development Authority to support additional feature development for its DeepView System, an AI driven burn wound imaging technology, alongside a company commitment of $9.7 million to total development costs (BARDA contract 75A50123C00049).Recent updates
MDAI: BARDA Funding And New Leadership Will Support Future Commercialization Potential
Analysts have updated their price targets on Spectral AI to reflect revised assumptions for discount rates, revenue growth, profit margins, and a higher forward P/E. These changes have resulted in a revised assessment of the potential upside in the shares.MDAI: BARDA Funding And Leadership Transition Will Support Future Burn Preparedness
Analysts have nudged their Spectral AI price target to $6.00, citing small adjustments to assumptions on discount rate, revenue trends, profit margins, and a very high future P/E multiple as key drivers of the updated view. What's in the News Spectral AI received $31.7 million in immediate, non dilutive funding from the Biomedical Advanced Research and Development Authority to support additional feature development for its DeepView System, an AI driven burn wound imaging technology, alongside a company commitment of $9.7 million to total development costs (BARDA contract 75A50123C00049).News Flash: Analysts Just Made A Stunning Upgrade To Their Spectral AI, Inc. (NASDAQ:MDAI) Forecasts
Mar 27
MDAI: BARDA Funding Will Support Future Burn Preparedness Commercialization Potential
Analysts have trimmed their price target on Spectral AI from $7.45 to $6.00 as they now apply a higher discount rate, expect a 28.16% decline in revenue growth, see profit margins at 12.86%, and use a much higher forward P/E multiple of 254.14x in their models. What's in the News Spectral AI received $31.7 million in immediate, non-dilutive funding from the U.S. Biomedical Advanced Research and Development Authority (BARDA) to accelerate additional features for its DeepView System, with the company committing a further $9.7 million of its own capital to the project (Key Developments).MDAI: New CEO Appointment Will Support Future Margin Recovery Potential
Analysts have trimmed their Spectral AI price target to $3.00, citing slightly higher discount rates, softer revenue growth expectations, a lower projected profit margin, and a higher assumed future P/E multiple in their updated model. What's in the News Spectral AI appointed Vincent S.MDAI: Leadership Transition And Commercialization Progress Will Support Future Margin Recovery
Narrative Update on Spectral AI Analysts have kept their Spectral AI price target steady at $3.00, with unchanged fair value assumptions and only small tweaks to the discount rate, revenue growth, profit margin, and future P/E inputs. These adjustments support a largely unchanged outlook.
Spectral AI: First of Its Kind Automated Wound Healing Prediction
Overview Spectral AI is an artificial intelligence business offering predictive wound diagnostics designed to facilitate faster and more accurate treatment decisions in wound care. Spectral’s shares are traded as NASDAQ: MDAI.MDAI: Contract Timing Shift Will Support Future Margin Recovery And Revenue Upside
Analysts have adjusted their price target on Spectral AI to reflect a slightly lower discount rate, a small change in expected revenue contraction, and an updated future P/E of about 86x, while keeping fair value steady at US$3.00. What's in the News Spectral AI revised its earnings guidance for fiscal year 2025, reducing expected revenue guidance from US$21.5 million to US$18.5 million.Spectral AI, Inc. (NASDAQ:MDAI) Stock Catapults 29% Though Its Price And Business Still Lag The Industry
Jan 27MDAI: Contract Timing Shift Will Support Future Margin And Revenue Upside
Analysts now estimate Spectral AI's fair value at US$3.00 per share, unchanged from the prior US$3.00 view, as minor adjustments to the discount rate, revenue outlook, profit margin and future P/E assumptions leave their overall price target the same. What's in the News Spectral AI revised its revenue guidance for fiscal 2025 to US$18.5 million from US$21.5 million, reflecting updated expectations for the year (company guidance).MDAI: Future Contract Timing Shift Will Support Stronger Profit Margins
Analysts have trimmed their price targets on Spectral AI to US$3.00, pointing to updated assumptions that include a slightly higher discount rate, a smaller revenue decline, a higher profit margin outlook, and a lower future P/E multiple of about 88x. What's in the News Spectral AI reduced its revenue guidance for fiscal 2025 from US$21.5 million to US$18.5 million, citing timing of work on its BARDA contract and effects from the current US government shutdown (Key Developments).MDAI Future Revenue Shift From Contracts Will Support Stronger Profit Margins
Analysts have trimmed their price target on Spectral AI to reflect a modestly lower fair value estimate of 3.0 dollars from 3.5 dollars. They cited slightly higher perceived risk, even as outlooks improve for revenue contraction and profit margins, along with a marginally more attractive future earnings multiple.Spectral AI, Inc. (NASDAQ:MDAI) Shares Could Be 26% Below Their Intrinsic Value Estimate
Nov 28The Market Doesn't Like What It Sees From Spectral AI, Inc.'s (NASDAQ:MDAI) Revenues Yet As Shares Tumble 27%
Nov 28At US$2.24, Is Spectral AI, Inc. (NASDAQ:MDAI) Worth Looking At Closely?
Oct 23Market Cool On Spectral AI, Inc.'s (NASDAQ:MDAI) Revenues Pushing Shares 25% Lower
Sep 06Spectral AI, Inc. (NASDAQ:MDAI) Released Earnings Last Week And Analysts Lifted Their Price Target To US$5.09
Aug 16Estimating The Intrinsic Value Of Spectral AI, Inc. (NASDAQ:MDAI)
Jul 29The Market Lifts Spectral AI, Inc. (NASDAQ:MDAI) Shares 50% But It Can Do More
Jun 22The Market Lifts Spectral AI, Inc. (NASDAQ:MDAI) Shares 50% But It Can Do More
Jun 22
FDA Submission Success Will Advance DeepView Global Opportunities
Successful burn validation study and international expansion strengthen FDA submission, potentially accelerating approval and driving future revenue growth.Take Care Before Jumping Onto Spectral AI, Inc. (NASDAQ:MDAI) Even Though It's 28% Cheaper
Mar 08Estimating The Intrinsic Value Of Spectral AI, Inc. (NASDAQ:MDAI)
Feb 10Investors Still Aren't Entirely Convinced By Spectral AI, Inc.'s (NASDAQ:MDAI) Revenues Despite 39% Price Jump
Dec 18Investors Still Aren't Entirely Convinced By Spectral AI, Inc.'s (NASDAQ:MDAI) Revenues Despite 43% Price Jump
Nov 03Slammed 25% Spectral AI, Inc. (NASDAQ:MDAI) Screens Well Here But There Might Be A Catch
Sep 19Shareholder Returns
| MDAI | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 13.9% | -4.0% | 0.6% |
| 1Y | 58.9% | -16.1% | 28.7% |
Return vs Industry: MDAI exceeded the US Medical Equipment industry which returned -18.1% over the past year.
Return vs Market: MDAI exceeded the US Market which returned 27.6% over the past year.
Price Volatility
| MDAI volatility | |
|---|---|
| MDAI Average Weekly Movement | 10.6% |
| Medical Equipment Industry Average Movement | 8.3% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: MDAI has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MDAI's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 65 | Vince Capone | www.spectral-ai.com |
Spectral AI, Inc., an artificial intelligence (AI) company, focuses on predictive medical diagnostics in the United States. The company offers DeepView System, which uses proprietary AI algorithms to distinguish between fully damaged, partially damaged, and healthy human tissue characteristics invisible to the naked eye at the initial time point of wound presentation and delivers a binary prediction on the wounds capacity to heal by a specified time point in the future to assist the physician in making a more accurate, timely, and informed decision regarding the treatment of the patient’s wounds. Its system also develops AI-Burn software and MSI imaging technology, which consists of proprietary multi-spectral optics and sensors that capture injured tissue images.
Spectral AI, Inc. Fundamentals Summary
| MDAI fundamental statistics | |
|---|---|
| Market cap | US$61.74m |
| Earnings (TTM) | -US$7.57m |
| Revenue (TTM) | US$19.65m |
Is MDAI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDAI income statement (TTM) | |
|---|---|
| Revenue | US$19.65m |
| Cost of Revenue | US$10.73m |
| Gross Profit | US$8.93m |
| Other Expenses | US$16.50m |
| Earnings | -US$7.57m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 12, 2026
| Earnings per share (EPS) | -0.24 |
| Gross Margin | 45.42% |
| Net Profit Margin | -38.53% |
| Debt/Equity Ratio | -146.5% |
How did MDAI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/30 13:41 |
| End of Day Share Price | 2026/04/30 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Spectral AI, Inc. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Gorman | BTIG |
| Carl Byrnes | Northland Capital Markets |
| Vadim Alexandre Khalil | SP Angel Corporate Finance LLP |